Ro 61-8048 inhibits kynurenine 3-hydroxylase, displaying anti-inflammatory and neuromodulatory activities. Ro 61-8048 is used to study kynurenine signaling in embryonic brain development. In models of trypanosomiasis, this compound decreases inflammation. In animal models of Parkinson’s disease, Ro 61-8048 decreases L-DOPA-induced dyskinesia.
| Cas No. | 199666-03-0 |
|---|---|
| Purity | ≥99% |
| Formula | C17H15N3O6S2 |
| Formula Wt. | 421.44 |
| IUPAC Name | 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide |
| Solubility | 100mM in DMSO 10mM in ethanol |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Pisar M, Forrest CM, Khalil OS, et al. Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Res. 2014 Aug 12;1576:1-17. PMID: 24956103.
Ouattara B, Belkhir S, Morissette M, et al. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci. 2009 Jun;38(2):128-42. PMID: 18704766.
Rodgers J, Stone TW, Barrett MP, et al. Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis. Brain. 2009 May;132(Pt 5):1259-67. PMID: 19339256.
